Company intelligence / Profile preview

Cergentis

Utrecht, Netherlands

Ownership: Private
Development stage: Other

Overview

Cergentis is a biotechnology company specializing in genetic analysis and quality control for advanced therapies—notably in cell and gene therapy—using its proprietary TLA platform. The company’s technology supports both research and development, helping to ensure genetic stability and clonal derivation of cell lines used in biopharmaceutical manufacturing. Cergentis was acquired by Solvias in July 2022 and now operates as part of their CMC analytical services, supporting clients from preclinical through commercialization.

Modalities: Gene therapyCell therapy
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Cergentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cergentis.

Explore the full profile